Dofetilide in Patients with Left Ventricular Dysfunction and either Heart Failure or Acute Myocardial Infarction: Rationale, Design, and Patient Characteristics of the DIAMOND Studies

Clinical Cardiology

Volumn 20, Issue 8, 1997, Pages 704-710

  Moller M ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Congestive heart failure; Dofetilide; Left ventricular dysfunction; Myocardial infarction; Prognosis

Indexed keywords

ANTIARRHYTHMIC AGENT; DOFETILIDE; PHENETHYLAMINE DERIVATIVE; POTASSIUM CHANNEL BLOCKING AGENT; SULFONAMIDE;

AGED; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENMARK; DOUBLE BLIND PROCEDURE; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; MALE; METHODOLOGY; MORTALITY; MULTICENTER STUDY; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SUDDEN DEATH;

AGED; ANTI-ARRHYTHMIA AGENTS; DEATH, SUDDEN, CARDIAC; DENMARK; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MYOCARDIAL INFARCTION; PATIENT SELECTION; PHENETHYLAMINES; POTASSIUM CHANNEL BLOCKERS; RESEARCH DESIGN; RISK FACTORS; SULFONAMIDES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0031204625     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960200808     Document Type: Article

References (25)

1. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene L, Huther L, Richardson DW, and the CAST Investigators: Mortality and morbidity in patients receiving encainide, flecainide or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324:781-788
2. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, Veltri EP: Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 1996 Jul 6 1996;348:7-12
3. Doval HC, Nul DR, Perrone SV, Bortman GR, Curiel R, for Grupo de Estudio de la Sobrevida en la Insufficiencia en Argentina (GESICA): Randomized trial of low dose amiodarone in severe congestive heart failure. Lancet 1994;344:493-498
4. Nicklas JM, McKenna WJ, Stewart RA, Mickelson JK, Das SK, Schork MA, Krikler SJ, Quain LA, Moradi F, Pitt B: Prospective, double blind controlled trial of low dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular eclopy. Am Heart J 1991;122:1016-1021
5. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, Massie BM, Colling C, Lazzeri D: Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure (see comments). N Engl J Med 1995;333:77-82
6. Julian D, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz P, Simon P, The European Myocardial Infarct Amiodarone Trial Investigators: Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997;349:667-674
7. Cairns JA, Conolly SJ, Roberts R, Gent M, The Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators: Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997;349:675-682
8. Gwilt M, Arrowsmith JE, Blackburn KJ, Burges RA, Cross PE, Dalrymple HW: UK-68,798: A novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells. J Pharmacol Exp Ther 1991;256:318-324
9. Knilans TK, Lathrop DA, Nanasi PP, Schwartz A, Varro A: Rate and concentration dependent effects of UK-68,798, a potent new class III antiarrhythmic on canine Purkinje fibre action potential duration and Vmax. Br J Pharmacol 1991;103:1568-1572
10. Rasmussen HS, Allen MJ, Blackburn KJ, Butrous GS, Dalrymple HW: Dofetilide, a novel class III antiarrhythmic agent. J Cardiovasc Pharmacol 1992;20:S96-S105
11. Sedgwick ML, Rasmussen HS, Cobbe SM: Clinical and electrophysiological effects of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with angina pectoris. Am J Cardiol 1992;69:513-517
12. Echt DS, Lee JT, Murray KT, Vorperian V, Borganelli SM, Crawford DM, Friedrich T, Roden DM: A randomized, double-blind, placebo-controlled, dose-ranging study of dofetilide in patients with inducible sustained ventricular tachyarrhythmias. J Cardiovasc Electrophysiol 1995;6:687-699
13. Conelly DT, Thomsen PEB, Camm AJ, Morgan JM, Jordaens L, Butrous GS: Efficacy and safety of dofetilide, a novel class III antiarrhythmic agent, in atrioventricular nodal reentrant tachycardia (abstr). Eur Heart J 1992;13:304
14. Wong CKY, Heald S, Thomsen PEB, Jordaens L, Conelly DT, Rasmussen HS: Electrophysiology, safety and efficacy of dofetilide in patients with atrioventricular reentrant tachycardia (AVRT) (abstr). Eur Heart J 1992;13:211
15. Kannel WB, Plehn JF, Cupples LA: Cardiac failure and sudden death in the Framingham study. Am Heart J 1988;115:869-875
16. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302
17. Køber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbæk J, Cole DS, Auclert L, Pauly NC, Aliot E, Persson S, Camm AJ, The TRACE Study Group: A clinical trial of the angiotensin converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333:1670-1676
18. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Guddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM, on behalf of the SAVE Invetigators: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992;327:669-677
19. Berning J, Rokkedal-Nielsen J, Launbjerg J, Fogh J, Mickley H, Andersen PE: Rapid estimation of left ventricular ejection traction in acute myocardial infarction by echocardiographic wall motion analysis. Cardiology 1992;80:257-266
20. Køber L, Torp-Pedersen C, Carlsen J, Videbæk R, Egeblad H, on behalf of the TRACE Study Group: An echocardiographic method for selecting high risk patients shortly after acute myocardial infarction, for inclusion in multicentre studies as used in the TRACE study. Eur Heart J 1994;15:1616-1620
21. Lachin JM: Introduction to sample size determination and power analysis for clinical trials. Cont Clin Trial 1981;2:93-113
22. Greene HL, Richardson DW, Barker AH, Roden DM, Capone RJ, Echt DS, Friedman LM, Gillespie MJ, Hallstrom AP, Verter J: Classification of deaths after myocardial infarction as arrhythmic or nonarrhythmic (the Cardiac Arrhythmia Pilot Study). Am J Cardiol 1989;63:1-6
23. Fananapazir L, Cropp A: Dofetilide (UK 68,798) prevents ventricular tachycardia on Holter and inducible sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy (abstr). J Am Coll Cardiol 1992;19:224A
24. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I, Silverman NH, Tajik AJ: Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr 1989;2:358-367
25. Berning J, Steensgaard-Hansen F: Early estimation of risk by echocardiographic determination of wall motion index in an unselected population with acute myocardial infarction. Am J Cardiol 1990;65:567-576